Nicholas Investment Partners, LP Day One Biopharmaceuticals, Inc. Transaction History

Nicholas Investment Partners, LP

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 13, 2024	BUY	$13.56 - $17.46 $792,568 - $1.02 Million	58,449 Added 19.27%	361,767 $5.98 Million
Q4 2023 Feb 07, 2024	SELL	$9.68 - $15.37 $18.3 Million - $29 Million	-1,885,336 Reduced 86.14%	303,318 $4.43 Million
Q3 2023 Nov 13, 2023	SELL	$11.22 - $14.86 $543,687 - $720,071	-48,457 Reduced 2.17%	2,188,654 $26.9 Million
Q2 2023 Aug 09, 2023	BUY	$11.74 - $14.47 $7.44 Million - $9.17 Million	633,721 Added 39.52%	2,237,111 $26.7 Million
Q1 2023 May 11, 2023	BUY	$12.75 - $23.41 $10.4 Million - $19.1 Million	816,836 Added 103.85%	1,603,390 $21.4 Million
Q4 2022 Feb 10, 2023	BUY	$18.77 - $22.0 $547,089 - $641,234	29,147 Added 3.85%	786,554 $16.9 Million
Q3 2022 Nov 14, 2022	BUY	$16.44 - $26.57 $12.5 Million - $20.1 Million	757,407 New	757,407 $15.2 Million

178

84M

144K

218K

Ticker DAWN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 73,461,104
Market Cap $1.01B
Description
Day One Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genetically defined cancers. Its lead product candidate is DAY101, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric pa...

Get notified when there are updates to the investment portfolio of Nicholas Investment Partners, LP, based on Form 13F filings with the SEC.

Stay updated on Nicholas Investment Partners, LP with notifications on news.